Skip to main content
Premium Trial:

Request an Annual Quote

Kyowa Hakko Kirin Using Activiomics' Phosphoproteomics Platform for Drug Discovery

NEW YORK (GenomeWeb News) – Activiomics announced recently a research deal with Kyowa Hakko Kirin for use of Activiomics' mass spectrometry-based technology to "elucidate signaling mechanism of lead compounds in relevant cell-based systems."

Under the deal, the Japanese pharmaceutical firm will use Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology to identify important biomarkers that can be used in the drug-discovery process.

Financial and other terms of the agreement were not disclosed.

TIQUAS uses mass spectrometry to detect and quantify phosphorylation sites from a cell or tissue extract, which can be used to discover which proteins and pathways are activated. Changes in phosphorylation status signal a change in protein activity.

The deal was signed as part of Activiomics' strategic partnership with BioFocus announced during the summer and is its first entry into the Japanese market, the company said. Based in London, Activiomics is a privately held spinout of the Barts Cancer Institute.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.